Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

SCOTT LAWRENCE FLEISCHAUER

Allopathic & Osteopathic Physicians Internal Medicine Medical Oncology

NPI
1285789065
CMS profile
57953
Location
ARLINGTON, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$2,731.92

3 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

By paying entity

PY2021 · entire year · sorted by reported total

Paying entityAmountRecords
Exelixis Inc. $1,470.00 1
Epizyme, Inc., $1,250.00 1
Gilead Sciences, Inc. $11.92 1

Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

SCOTT LAWRENCE FLEISCHAUER

NPI 1285789065 · CMS profile ID 57953

Allopathic & Osteopathic Physicians / Internal Medicine / Medical Oncology

ARLINGTON, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1285789065?year=2021&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
SCOTT LAWRENCE FLEISCHAUER, NPI 1285789065, CMS profile ID 57953. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1285789065?year=2021&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). SCOTT LAWRENCE FLEISCHAUER, NPI 1285789065, CMS profile ID 57953. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1285789065?year=2021&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
SCOTT LAWRENCE FLEISCHAUER, NPI 1285789065, CMS profile ID 57953, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1285789065?year=2021&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

3 matching records · $2,731.92 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 3 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–3 of 3.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Gilead Sciences, Inc. $11.9206/01/2021 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845873003 CMS
Exelixis Inc. $1,470.0005/20/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 838866681 CMS
Epizyme, Inc., $1,250.0003/26/2021 Honoraria No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 832339541 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $76.24 8
PY2020 $18.82 2
PY2021 $2,731.92 3
PY2022 $1,144.93 5
PY2023 $23.72 1
PY2024 $84.25 4
PY2025 $290.60 12

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2023 Principal investigator $82,946.55 11
PY2022 Principal investigator $30,457.88 33
PY2021 Principal investigator $116,928.89 44
PY2020 Recipient $656.00 1
PY2020 Principal investigator $144,873.80 55
PY2019 Recipient $3,698.00 1
PY2019 Principal investigator $153,312.17 57

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2020

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

56 records in PY2020

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Incyte Corporation $1,147.78 12/17/2020 Non-covered Recipient Entity
TEXAS ONCOLOGY
A Phase 2, Open Label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy No dispute reported 06/30/2026 744299709
Principal investigator 1 Seagen Inc. $2,720.00 12/15/2020 Non-covered Recipient Entity
ARLINGTON CANCER CENTER
A Phase 2 Open-label Study of Brentuximab Vedotin in Front-line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above No dispute reported 06/30/2026 733455393
Principal investigator 1 Seagen Inc. $151.00 11/15/2020 Non-covered Recipient Entity
ARLINGTON CANCER CENTER
A Phase 2 Open-label Study of Brentuximab Vedotin in Front-line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above No dispute reported 06/30/2026 733455389
Principal investigator 1 Seagen Inc. $175.00 11/15/2020 Non-covered Recipient Entity
ARLINGTON CANCER CENTER
A Phase 2 Open-label Study of Brentuximab Vedotin in Front-line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above No dispute reported 06/30/2026 733455391
Principal investigator 1 PFIZER INC. $1,250.00 10/17/2020 Non-covered Recipient Entity
US Oncology Research LLC
PHASE 2 STUDY IN PATIENTS WITH NEOADJUVANT BREAST CANCER No dispute reported 06/30/2026 742911699
Principal investigator 1 Incyte Corporation $850.00 10/15/2020 Non-covered Recipient Entity
TX ONC : ARLINGTON / W MAYFIELD RD
A Phase 2, Open Label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy No dispute reported 06/30/2026 744273155
Principal investigator 1 Incyte Corporation $489.00 10/15/2020 Non-covered Recipient Entity
TX ONC : ARLINGTON / W MAYFIELD RD
A Phase 2, Open Label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy No dispute reported 06/30/2026 744273157
Principal investigator 1 Pharmacyclics LLC, An AbbVie Company $190.00 10/15/2020 Non-covered Recipient Entity
Oncology Pharmacy Services
PCYC-1134M-CA No dispute reported 06/30/2026 727739655
Principal investigator 1 Pharmacyclics LLC, An AbbVie Company $638.00 10/15/2020 Non-covered Recipient Entity
Oncology Pharmacy Services
PCYC-1134M-CA No dispute reported 06/30/2026 727740703
Principal investigator 1 Pharmacyclics LLC, An AbbVie Company $190.00 09/15/2020 Non-covered Recipient Entity
Oncology Pharmacy Services
PCYC-1134M-CA No dispute reported 06/30/2026 727733973
Principal investigator 1 Seagen Inc. $2,720.00 09/15/2020 Non-covered Recipient Entity
ARLINGTON CANCER CENTER
A Phase 2 Open-label Study of Brentuximab Vedotin in Front-line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above No dispute reported 06/30/2026 733455345
Principal investigator 1 Pharmacyclics LLC, An AbbVie Company $190.00 08/15/2020 Non-covered Recipient Entity
Oncology Pharmacy Services
PCYC-1134M-CA No dispute reported 06/30/2026 727733313
Principal investigator 1 PFIZER INC. $1,250.00 07/30/2020 Non-covered Recipient Entity
US Oncology Research LLC
PHASE 2 STUDY IN PATIENTS WITH NEOADJUVANT BREAST CANCER No dispute reported 06/30/2026 742910349
Recipient Eli Lilly and Company $656.00 07/21/2020 Covered Recipient Physician A RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY OF ABEMACICLIB COMBINED WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE IN PATIENTS WITH HIGH RISK, NODE POSITIVE, EARLY STAGE, HORMONE RECEPTOR POSITIVE, HUMAN EPIDERMAL RECEPTOR 2 NEGATIVE, BREAST CANCER No dispute reported 06/30/2026 728724891
Principal investigator 1 Incyte Corporation $850.00 07/15/2020 Non-covered Recipient Entity
TX ONC : ARLINGTON / W MAYFIELD RD
A Phase 2, Open Label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy No dispute reported 06/30/2026 744273123
Principal investigator 1 Pharmacyclics LLC, An AbbVie Company $638.00 07/15/2020 Non-covered Recipient Entity
Oncology Pharmacy Services
PCYC-1134M-CA No dispute reported 06/30/2026 727734941
Principal investigator 1 Seagen Inc. $815.00 07/15/2020 Non-covered Recipient Entity
ARLINGTON CANCER CENTER
A Phase 2 Open-label Study of Brentuximab Vedotin in Front-line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above No dispute reported 06/30/2026 733455341
Principal investigator 1 Seagen Inc. $175.00 07/15/2020 Non-covered Recipient Entity
ARLINGTON CANCER CENTER
A Phase 2 Open-label Study of Brentuximab Vedotin in Front-line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above No dispute reported 06/30/2026 733455343
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $1,000.00 07/07/2020 Non-covered Recipient Entity
Us Oncology Res Llc
A Master Protocol of Phase II Studies of Nivolumab in Advanced NSCLC: Nivolumab as Maintenance after Induction Chemotherapy or as First Line Treatment, Alone or in Combination of Standard of Care Therapies No dispute reported 06/30/2026 736764667
Principal investigator 1 Pharmacyclics LLC, An AbbVie Company $190.00 06/15/2020 Non-covered Recipient Entity
Oncology Pharmacy Services
PCYC-1134M-CA No dispute reported 06/30/2026 727728697
Principal investigator 1 Pharmacyclics LLC, An AbbVie Company $638.00 06/15/2020 Non-covered Recipient Entity
Oncology Pharmacy Services
PCYC-1134M-CA No dispute reported 06/30/2026 727729160
Principal investigator 1 Seagen Inc. $1,056.00 06/15/2020 Non-covered Recipient Entity
ARLINGTON CANCER CENTER
A Phase 2 Open-label Study of Brentuximab Vedotin in Front-line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above No dispute reported 06/30/2026 733455271
Principal investigator 1 Seagen Inc. $1,056.00 06/15/2020 Non-covered Recipient Entity
ARLINGTON CANCER CENTER
A Phase 2 Open-label Study of Brentuximab Vedotin in Front-line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above No dispute reported 06/30/2026 733455305
Principal investigator 1 BeiGene, Ltd. $56,376.00 06/01/2020 Non-covered Recipient Entity
Texas Oncology-Arlington South
A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Intolerant of Prior Treatment with Ibrutinib No dispute reported 06/30/2026 753001161
Principal investigator 1 PFIZER INC. $1,250.00 05/28/2020 Non-covered Recipient Entity
US Oncology Research LLC
PHASE 2 STUDY IN PATIENTS WITH NEOADJUVANT BREAST CANCER No dispute reported 06/30/2026 742909513
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $5,861.00 05/21/2020 Non-covered Recipient Entity
Us Oncology Res Llc
Hodgkin Lymphoma Molecular Profiling and Clinical Outcomes in U.S. Community Oncology Practices No dispute reported 06/30/2026 736764313
Principal investigator 1 Seagen Inc. $2,720.00 05/15/2020 Non-covered Recipient Entity
ARLINGTON CANCER CENTER
A Phase 2 Open-label Study of Brentuximab Vedotin in Front-line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above No dispute reported 06/30/2026 733455267
Principal investigator 1 Amgen Inc. $1,680.00 04/15/2020 Non-covered Recipient Entity
TEXAS ONCOLOGY- ARLINGTON NORTH
Prospective Observational Study of Onpro vs SOC. No dispute reported 06/30/2026 731642417
Principal investigator 1 Incyte Corporation $850.00 04/15/2020 Non-covered Recipient Entity
TX ONC : ARLINGTON / W MAYFIELD RD
A Phase 2, Open Label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy No dispute reported 06/30/2026 744273121
Principal investigator 1 Seagen Inc. $175.00 04/15/2020 Non-covered Recipient Entity
ARLINGTON CANCER CENTER
A Phase 2 Open-label Study of Brentuximab Vedotin in Front-line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above No dispute reported 06/30/2026 733455257
Principal investigator 1 Seagen Inc. $1,131.00 04/15/2020 Non-covered Recipient Entity
ARLINGTON CANCER CENTER
A Phase 2 Open-label Study of Brentuximab Vedotin in Front-line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above No dispute reported 06/30/2026 733455259
Principal investigator 1 Seagen Inc. $1,206.00 04/15/2020 Non-covered Recipient Entity
ARLINGTON CANCER CENTER
A Phase 2 Open-label Study of Brentuximab Vedotin in Front-line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above No dispute reported 06/30/2026 733455261
Principal investigator 1 Eli Lilly and Company $0.04 04/01/2020 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
A RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY OF ABEMACICLIB COMBINED WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE IN PATIENTS WITH HIGH RISK, NODE POSITIVE, EARLY STAGE, HORMONE RECEPTOR POSITIVE, HUMAN EPIDERMAL RECEPTOR 2 NEGATIVE, BREAST CANCER No dispute reported 06/30/2026 728749881
Principal investigator 1 Incyte Corporation $489.00 03/15/2020 Non-covered Recipient Entity
TX ONC : ARLINGTON / W MAYFIELD RD
A Phase 2, Open Label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy No dispute reported 06/30/2026 744273115
Principal investigator 1 Pharmacyclics LLC, An AbbVie Company $190.00 03/15/2020 Non-covered Recipient Entity
Oncology Pharmacy Services
PCYC-1134M-CA No dispute reported 06/30/2026 727723573
Principal investigator 1 Pharmacyclics LLC, An AbbVie Company $190.00 03/15/2020 Non-covered Recipient Entity
Oncology Pharmacy Services
PCYC-1134M-CA No dispute reported 06/30/2026 727724145
Principal investigator 1 Seagen Inc. $175.00 03/15/2020 Non-covered Recipient Entity
ARLINGTON CANCER CENTER
A Phase 2 Open-label Study of Brentuximab Vedotin in Front-line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above No dispute reported 06/30/2026 733455247
Principal investigator 1 Seagen Inc. $1,281.00 03/15/2020 Non-covered Recipient Entity
ARLINGTON CANCER CENTER
A Phase 2 Open-label Study of Brentuximab Vedotin in Front-line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above No dispute reported 06/30/2026 733455249
Principal investigator 1 Seagen Inc. $1,281.00 03/15/2020 Non-covered Recipient Entity
ARLINGTON CANCER CENTER
A Phase 2 Open-label Study of Brentuximab Vedotin in Front-line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above No dispute reported 06/30/2026 733455251
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $3,135.00 02/25/2020 Non-covered Recipient Entity
Us Oncology Res Llc
A Master Protocol of Phase II Studies of Nivolumab in Advanced NSCLC: Nivolumab as Maintenance after Induction Chemotherapy or as First Line Treatment, Alone or in Combination of Standard of Care Therapies No dispute reported 06/30/2026 736764595
Principal investigator 1 Seagen Inc. $1,350.00 02/15/2020 Non-covered Recipient Entity
ARLINGTON CANCER CENTER
A Phase 2 Open-label Study of Brentuximab Vedotin in Front-line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above No dispute reported 06/30/2026 733455239
Principal investigator 1 Seagen Inc. $2,620.00 02/15/2020 Non-covered Recipient Entity
ARLINGTON CANCER CENTER
A Phase 2 Open-label Study of Brentuximab Vedotin in Front-line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above No dispute reported 06/30/2026 733455241
Principal investigator 1 Seagen Inc. $2,720.00 02/15/2020 Non-covered Recipient Entity
ARLINGTON CANCER CENTER
A Phase 2 Open-label Study of Brentuximab Vedotin in Front-line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above No dispute reported 06/30/2026 733455243
Principal investigator 1 Seagen Inc. $1,020.00 02/15/2020 Non-covered Recipient Entity
ARLINGTON CANCER CENTER
A Phase 2 Open-label Study of Brentuximab Vedotin in Front-line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above No dispute reported 06/30/2026 733455245
Principal investigator 1 Incyte Corporation $1,147.78 02/13/2020 Non-covered Recipient Entity
TX ONC : ARLINGTON / W MAYFIELD RD
A Phase 2, Open Label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy No dispute reported 06/30/2026 744273107
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $2,779.20 02/03/2020 Non-covered Recipient Entity
Us Oncology Res Llc
A Phase IIIb/IV Safety Trial of Nivolumab (BMS-936558) in Subjects with Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Progressed During or After Receiving At Least One Prior Systemic Regimen No dispute reported 06/30/2026 736764451
Principal investigator 1 Amgen Inc. $6,272.00 01/30/2020 Non-covered Recipient Entity
US ONC RESEARCH LLC
Prospective Observational Study of Onpro vs SOC. No dispute reported 06/30/2026 731642895
Principal investigator 1 Eli Lilly and Company $4,439.00 01/28/2020 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
A RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY OF ABEMACICLIB COMBINED WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE IN PATIENTS WITH HIGH RISK, NODE POSITIVE, EARLY STAGE, HORMONE RECEPTOR POSITIVE, HUMAN EPIDERMAL RECEPTOR 2 NEGATIVE, BREAST CANCER No dispute reported 06/30/2026 728751369
Principal investigator 1 Amgen Inc. $2,330.00 01/15/2020 Non-covered Recipient Entity
TEXAS ONCOLOGY, P.A.
Prospective Observational Study of Onpro vs SOC. No dispute reported 06/30/2026 731642624
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $2,801.00 01/15/2020 Non-covered Recipient Entity
Texas Oncology
SUSTAIN, event driven trial No dispute reported 06/30/2026 736762641
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $2,700.00 01/15/2020 Non-covered Recipient Entity
Texas Oncology
Phase IIIb IV Safety Trial of Nivolumab BMS-936558 in Subjects with Advanced or Metastatic Non-Small Cell Lung Cancer No dispute reported 06/30/2026 736762677
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $7,378.00 01/15/2020 Non-covered Recipient Entity
Texas Oncology
Hodgkin Lymphoma Molecular Profiling and Clinical Outcomes in US Community Oncology Practices No dispute reported 06/30/2026 736762849
Principal investigator 1 Eli Lilly and Company $9,010.00 01/15/2020 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
A RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY OF ABEMACICLIB COMBINED WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE IN PATIENTS WITH HIGH RISK, NODE POSITIVE, EARLY STAGE, HORMONE RECEPTOR POSITIVE, HUMAN EPIDERMAL RECEPTOR 2 NEGATIVE, BREAST CANCER No dispute reported 06/30/2026 728749577
Principal investigator 1 Incyte Corporation $850.00 01/15/2020 Non-covered Recipient Entity
TX ONC : ARLINGTON / W MAYFIELD RD
A Phase 2, Open Label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy No dispute reported 06/30/2026 744273113
Principal investigator 1 Pharmacyclics LLC, An AbbVie Company $638.00 01/15/2020 Non-covered Recipient Entity
Oncology Pharmacy Services
PCYC-1134M-CA No dispute reported 06/30/2026 727724133
Principal investigator 1 Seagen Inc. $450.00 01/15/2020 Non-covered Recipient Entity
ARLINGTON CANCER CENTER
A Phase 2 Open-label Study of Brentuximab Vedotin in Front-line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above No dispute reported 06/30/2026 733455235